Thumbnail

CONGENITAL HEART DISEASE MARKET - PIPELINE INTELLIGENCE, 2020

Looking to buy the report?

Introduction

The word “congenital” means existing at birth. When the heart vessels or blood vessels near the heart do not develop normally, it leads to congenital heart disease or defects (CDH). In medical terminology, this disease is either considered cyanotic or acyanotic. In both cases, the heart is not able to pump the blood as efficiently as it should. In most cases, the cause of disease origin is not identifiable, or there are no specific reasons, like a mother having a disease while pregnant and taking medications, such as antiseizure medicines or the acne medication isotretinoin. Other symptoms include rapid heartbeat, rapid breathing, and swelling of the legs, among others.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.

Congenital Heart Disease Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for congenital heart disease indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Congenital Heart Disease Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for the clinical trials, globally. It covers concise information of registered clinical trials in different countries across several developed and emerging markets
  • There is a growing need to spread awareness regarding CHD. A broad range of initiatives to educate the patients and families is important, to advance the care and improve the treatment of this population. Prescribing antibiotics for CHD is no longer recommended, except in some cases. The demand to find more cost-effective alternatives drives the demand for pipeline growth for CHD

Key Sponsors in Congenital Heart Disease Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy

 

1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy